Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,899,890

« Back to Dashboard

Which drugs does patent 6,899,890 protect, and when does it expire?

Patent 6,899,890 protects CLINDESSE and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 6,899,890

Title:	Bioadhesive drug delivery system
Abstract:	The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.
Inventor(s):	Kirschner; Mitchell I. (St. Louis, MO), Levinson; R. Saul (Chesterfield, MO), Riley; Thomas C. (Manchester, MO), Hermelin; Marc S. (St. Louis, MO)
Assignee:	KV Pharmaceutical Company (St. Louis, MO)
Application Number:	10/101,014
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,899,890
Patent Claim Types: see list of patent claims	Compound; Delivery; Composition; Dosage form; Use;

Drugs Protected by US Patent 6,899,890

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Perrigo Pharma Intl	CLINDESSE	clindamycin phosphate	CREAM;VAGINAL	050793-001	Nov 30, 2004		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			METHOD OF TREATING BACTERIAL VAGINOSIS	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

International Family Members for US Patent 6,899,890

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	039037	➤ Sign Up
Australia	2002300175	➤ Sign Up
Australia	2003218233	➤ Sign Up
Brazil	0202767	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva

Moodys

Merck

Farmers Insurance

Harvard Business School

Citi

Colorcon

Cantor Fitzgerald

Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.